Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

[Background] Concerns have been raised about the possibility that inhibitors of the renin–angiotensin–aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since...

Descripción completa

Detalles Bibliográficos
Autores: de Abajo, Francisco J., Rodríguez-Martín, Sara, Lerma, Victoria, Mejía, Gina, Aguilar, Mónica, García-Luque, Amelia, Laredo, Leonor, Laosa, Olga, Centeno-Soto, Gustavo A., Gálvez, Maria Ángeles, Puerro, Miguel, Gonzalez-Rojano, Esperanza, Pedraza, Laura, Pablo, Itziar de, Abad-Santos, Francisco, Rodríguez-Mañas, Leocadio, Gil, Miguel, Tobías, Aurelio, Rodríguez-Miguel, Antonio, Rodríguez-Puyol, Diego
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/211998
Acceso en línea:http://hdl.handle.net/10261/211998
Access Level:acceso abierto
Descripción
Sumario:[Background] Concerns have been raised about the possibility that inhibitors of the renin–angiotensin–aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19.